Lanqing Cao

Dr. Lanqing Cao


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2020 in Pathology - Research and Practice
Verified
Journal Article
Closed access
LCLanqing Cao
Lanqing Cao
PSPing-Li Sun
Ping-Li Sun
YHYangyang He
Yangyang He
MYMin Yao
Min Yao
HGHongwen Gao
Hongwen Gao

9 November 2020 in Journal of Gastrointestinal Surgery
Verified
Journal Article
Closed access
PDF file
LCLanqing Cao
Lanqing Cao
ZWZhaoyong Wang
Zhaoyong Wang
LDLiwei Duan
Liwei Duan
ljwei@jlu.edu.cnLijuan Weiljwei@jlu.edu.cnLijuan Wei
ljwei@jlu.edu.cnLijuan Wei

23 March 2025 in Human Pathology
Verified
Journal Article
Closed access
DHDong He
Dong He
LJLonghai Jin
Longhai Jin
HGHanhan Geng
Hanhan Geng
LCLanqing Cao
Lanqing Cao

7 July 2026 in iScience
Verified
Journal Article
Open access
DHDong He
Dong He
LJLonghai Jin
Longhai Jin
XMXianglin Mei
Xianglin Mei
MJMeng Jia
Meng Jia
ZWZhaoyong Wang
Zhaoyong Wang
LCLanqing Cao
Lanqing Cao
Pathological gross examination guides tissue sampling in heterogeneous ovarian tumors, where mixed components can complicate selection of representative regions. We evaluated whether a generalist large vision-language model can support gross image analysis through pathology-informed in-context exemplars. Using Qwen-2.5-Vision-Language-72B, we developed single-component exemplar optimization and histology-guided exemplar optimization to promote component-aware reasoning and region-level risk flagging. In a single-institution retrospective cohort, the optimized eight-shot strategy achieved 89.8% image-level accuracy on mixed ovarian tumors and improved region-level demarcation relevant to sampling. In borderline tumors with microinvasion or microinvasive carcinoma, model-identified regions encompassed pathologist-defined sampling areas, supporting risk flagging rather than stand-alone diagnosis. In rare malignant tumors (n = 21), the same strategy achieved 90.5% image-level accuracy. These findings suggest that domain-aligned exemplar design can enhance in-context reasoning for grossing-oriented medical image analysis.

7 September 2026 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
XZXue Zhao
Xue Zhao
HWHan Wang
Han Wang
YLYanan Liu
Yanan Liu
LCLanqing Cao
Lanqing Cao
Immune checkpoint blockade (ICB) produces durable tumor control in a subset of patients, yet resistance is usually interpreted through tumor-intrinsic lesions or suppression within the tumor microenvironment (TME). We propose that ICB resistance can also be organized as failure of a multiscale antitumor immune circuit comprising local immune execution, regional immune education in tumor-draining lymph nodes (TDLNs), and systemic immune calibration by the host. In this model, “hierarchical” denotes nested functional dependence rather than one-way anatomical control: local killing depends probabilistically on antigen visibility, access, and a renewable supply of tumor-reactive cells; nodal priming depends on competent dendritic-cell licensing and host immune fitness; and reciprocal feedback can propagate or repair failure across compartments. We first define the canonical CD8-dominant substrate that ICB can amplify, including cross-presentation, costimulation, progenitor-exhausted T-cell maintenance, trafficking, and target-cell recognition, while retaining alternative CD4, natural killer, intratumoral antigen-presenting-cell, and tertiary lymphoid routes. We then evaluate local, regional, and systemic resistance mechanisms, four directional feedback axes, and context-dependent patterns in pancreatic cancer, melanoma, non-small-cell lung cancer, microsatellite-stable colorectal cancer, hepatocellular carcinoma, and prostate cancer. Evidence from animal perturbation, human spatial and clonal studies, and clinical trials supports individual circuit components but remains heterogeneous. Randomized perioperative regimens demonstrate disease- and setting-specific benefit, whereas negative randomized results and mixed or limiting early-phase signals across innate agonism, stromal or metabolic targeting, radiotherapy combinations, and systemic conditioning constrain therapeutic extrapolation. We therefore present compartment-resolved biomarkers and adaptive trial designs as research hypotheses, not a validated classifier or standard-care algorithm. The framework will be useful only if prespecified multiscale measurements improve prediction beyond tumor-only models and if mechanism-matched interventions produce the expected pharmacodynamic repair before clinical benefit is attributed to the circuit.